CD8A and neoplasm: So, they performed a triple combined therapy involving USP8 inhibitor (DUB-IN-2), SAS and anti-PD-1-antibody observing an increased in tumor infiltrating CD8+ T-cells and a reduction of murine colon tumor, selected as in vivo model, in a strong significant statistically manner, compared to the other conditions.